The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term follow-up of “adjuvant” pembrolizumab following locally ablative therapy for oligometastatic non-small cell lung cancer.
 
David John Cantor
No Relationships to Disclose
 
Christiana Davis
No Relationships to Disclose
 
Christine Agnes Ciunci
Honoraria - Imedex/HMP; Merck
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); MacroGenics (Inst); Merck (Inst)
 
Charu Aggarwal
Consulting or Advisory Role - AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim; Celgene; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech; Janssen; Lilly; Merck; Pfizer; Sanofi/Regeneron; Shionogi; Turning Point Therapeutics
Speakers' Bureau - AstraZeneca (I); Roche/Genentech (I)
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Incyte (Inst); Macrogenics (Inst); Merck Sharp & Dohme (Inst)
 
Tracey L. Evans
Stock and Other Ownership Interests - Immunome (I)
Honoraria - AstraZeneca; Bristol Myers Squibb Foundation; Genentech; Genentech (I); Guardant Health; Jazz Pharmaceuticals; Merck; Mirati Therapeutics
Consulting or Advisory Role - AstraZeneca; Genentech; Genentech (I); Guardant Health
Speakers' Bureau - AstraZeneca; Bristol Myers Squibb Foundation; Genentech; Genentech (I); Guardant Health; Merck; Mirati Therapeutics
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Genentech (I); Guardant Health; Mirati Therapeutics
 
Evan W. Alley
No Relationships to Disclose
 
Roger B. Cohen
Honoraria - AstraZeneca
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Cantargia AB; Coherus Biosciences; Fstar Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); F-Star Biotechnology (Inst); Innate Pharma (Inst); Macrogenics (Inst); Xencor (Inst)
 
Joshua Michael Bauml
Employment - Janssen Research & Development
Consulting or Advisory Role - AstraZeneca; Ayala Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Foundation Medicine; Genentech; Guardant Health; Inivata; Janssen; Merck; Novartis; Novartis; Regeneron; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Carevive Systems (Inst); Incyte (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
 
Corey J. Langer
Honoraria - AstraZeneca; Genentech/Roche; Lilly/ImClone; Merck; Takeda Science Foundation
Consulting or Advisory Role - Abbott Biotherapeutics; ARIAD; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Gilead Sciences; Lilly/ImClone; Merck; Novocure; Pfizer; Regeneron; Takeda
Research Funding - Advantagene (Inst); Amgen; Ariad (Inst); AstraZeneca; Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte; Inovio Pharmaceuticals (Inst); Johnson & Johnson/Janssen; Lilly; Merck (Inst); Stem CentRx (Inst); Trizell (Inst)
Other Relationship - Amgen; Lilly; OncoCyte; Peregrine Pharmaceuticals; Synta